GenSight Biologics (SIGHT.PA)

Executive Summary

GenSight Biologics is a clinical-stage gene therapy company focused on mitochondrial diseases, primarily Leber Hereditary Optic Neuropathy (LHON) caused by ND4 mutations. Its lead candidate, Lumevoq (lenadogene nolparvovec), has completed two Phase 3 trials (REVERSE and RESCUE) and a long-term follow-up study, demonstrating sustained visual improvement. The company has filed for marketing authorization in Europe (EMA) and is preparing a U.S. filing (FDA). With a proprietary mitochondrial-targeting platform, GenSight aims to address retinal neurodegenerative diseases. The path to approval is uncertain, but positive regulatory outcomes could unlock significant value given the lack of approved gene therapies for LHON.

Upcoming Catalysts (preview)

• Q4 2026EMA marketing authorization decision for Lumevoq60% success
• Q2 2026FDA BLA submission for Lumevoq70% success
• TBDPhase 2/3 data readout for GS010 in retinitis pigmentosa30% success